Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 5008-5019

  Zhang, Cathy C ^a   Pavlicek, Adam ^a,b   Zhang, Qin ^a   Lira, Maruja E ^a   Painter, Cory L ^a   Yan, Zhengming ^a   Zheng, Xianxian ^a   Lee, Nathan V ^a   Ozeck, Mark ^a   Qiu, Ming ^a   Zong, Qing ^a   Lappin, Patrick B ^a   Wong, Anthony ^a   Rejto, Paul A ^a   Smeal, Tod ^a   Christensen, James G ^a  

^a PFIZER INC   (United States)

^b REGULUS THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PF 3084014;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CELL RENEWAL; CONTROLLED STUDY; DRUG RESPONSE; GENE; HES3 GENE; HES4 GENE; HEY2 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOPLASM METASTASIS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION; TETRAHYDRONAPHTHALENES; TUMOR MARKERS, BIOLOGICAL; VALINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866431367     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1379     Document Type: Article

References (32)

1. Dickson BC, Mulligan AM, Zhang H, Lockwood G, O'Malley FP, Egan SE, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol 2007;20:685-93.
2. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005;65:8530-7.
3. Robinson DR, Kalyana-Sundaram S,WuY-M, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med 2011;17:1646-51.
4. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004;167:215-21.
5. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer 2011;11:338-51.
6. Schwanbeck R, Martini S, Bernoth K, Just U. The Notch signaling pathway: Molecular basis of cell context dependency. Eur J Cell Biol 2011;90:572-81.
7. Claxton S, Fruttiger M. Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 2004;5:123-7.
8. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444:1083-7.
9. Benedito R, Roca C, Sörensen I, Adams S, Gossler A, Fruttiger M, et al. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009;137:1124-35.
10. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005;8:13-23.
11. Mikhailik A, Mazella J, Liang S, Tseng L. Notch ligand-dependent gene expression in human endometrial stromal cells. Biochem Biophys Res Commun 2009;388:479-82.
12. Sweeney C, Morrow D, Birney YA, Coyle S, Hennessy C, Scheller A, et al. Notch 1 and 3 receptors modulate vascular smooth muscle cell growth, apoptosis and migration via a CBF-1/RBP-Jk dependent pathway. FASEB J 2004;18:1421-3.
13. Sethi N, Dai X, Winter CG, Kang Y. Tumor-derived Jagged1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011;19:192-205.
14. Al-Husaini H, Subramanyam D, Reedijk MJ, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther 2011;10:9-15.
15. Hoey T, Yen WC, Axelrod F, Basi J, Donigian L, Dylla S, et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 2009;5:168-77.
16. Luistro L, He W, Smith M, Packman K, Vilenchik M, Carvajal D, et al. Preclinical profile of a potent γ-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res 2009;69:7672-80.
17. Konishi J, Kawaguchi KS, Vo H, Haruki N, Gonzalez A, Carbone DP, et al. γ-Secretase inhibitor prevents notch3 activation and reduces proliferation in human lung cancers. Cancer Res 2007;67:8051-7.
18. Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther 2010;9:1618-28.
19. Donovan D, Brown NJ, Bishop ET, Lewis CE. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 2001;4:113-21.
20. Hwang-VersluesWW,Kuo W-H, Chang P-H, Pan C-C, Wang H-H, Tsai S-T, et al. Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One 2009;4:e8377.
21. Grimm J, Kirsch DG, Windsor SD, Kim CF, Santiago PM, Ntziachristos V, et al. Use of gene expression profiling to direct in vivo molecular imaging of lung cancer. Proc Natl Acad Sci U S A 2005;102:14404-9.
22. Smyth GK. Limma: linear models for microarray data In:Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, editors. Bioinformatics and computational biology solutions using R and bioconductor. New York: Springer; 2005:397-420.
23. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodological) 1995;57:289-300.
24. Gentleman R. Reproducible Research: A Bioinformatics case study. Stat Appl Genet Mol 2005;4: Article 2.
25. Leisch F. Sweave: Dynamic generation of statistical reports using literate data analysis. In:Härdle W, Rönz B, editors. Proceedings in Computational Statistics. Berlin, Germany: Springer Compstat 2002: 575-80.
26. Li J-L, Harris AL. Notch signaling from tumor cells: A new mechanism of angiogenesis. Cancer Cell 2005;8:1-3.
27. Parker BS, Argani P, Cook BP, Liangfeng H, Chartrand SD, Zhang M, et al. Alterations in vascular gene expression in invasive breast carcinoma. Cancer Res 2004;64:7857-66.
28. Rao SS, O'Neil J, Liberator CD, Hardwick JS, Dai X, Zhang T, et al. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 2009;69:3060-8.
29. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011;121:3804-9.
30. Paris D, Quadros A, Patel N, DelleDonne A, Humphrey J, Mullan M. Inhibition of angiogenesis and tumor growth by [beta] and [gamma]-secretase inhibitors. Eur J Pharmacol 2005;514:1-15.
31. Leong KG, Niessen K, Kulic I, Raouf A, Eaves C, Pollet I, et al. Jagged1-mediated Notch activation induces epithelial-to-mesenchymal transition through Slug-induced repression of E-cadherin. J Exp Med 2007;204:2935-48.
32. Yang Y, Ahn YH, Gibbons DL, Zang Y, Lin W, Thilaganathan N, et al. The Notch ligand Jagged2 promotes lung adenocarcinoma metastasis through a miR-200-dependent pathway in mice. J Clin Invest 2011;121:1373-85.